primary study the effect of Galbanic acid on the efficacy of radiation therapy on c26 tumor cells implanted in Balb-C mice

Document Type : Original Paper

Authors

1 Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Associate Professor of Medical Physics, Research Center of Medical Physics, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Pharmacognosy and Biotechnology, Biotechnology Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences,Mashhad, Iran

4 - Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

6 Faculty of Veterinary Medicine, University of Zabol, Zabol, Iran

Abstract

Background: Radiosensitizers are drugs that make cancer cells more sensitive to radiation and cause more tumor cell death. The present study aimed to evaluate the radiosensitizing properties of Galbanic acid (GBA) on Colon cancer cells implanted in Balb-c mice.

Material and methods: After tumorigenesis, the mice were divided into 4 groups and were treated with radiation alone, drug alone, and combination therapy (radiation and drug). The fourth group (group control) received sham treatment. Life span, tumor volume and weight of the mice were evaluated.

Results: The results showed that GBA causes the toxicity of tumor cells, and the combined treatment of GBA and radiation effectively improves the efficiency of radiation therapy.

Conclusion: Current findings identify GBA as a good radiosensitizing agent. However, further research is required to determine the molecular mechanisms of the observed effect both in vitro and in vivo. It is also suggested that the radiosensitization effect of GBA on other cell types should be studied in the future.

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 09 April 2023
  • Receive Date: 30 July 2022
  • Revise Date: 03 March 2023
  • Accept Date: 09 April 2023